Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMO

Opinion
Video

Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.

Recent Videos
Marion Munk, MD, PhD, presenting slides
Related Content
4DMT announces the publication of preclinical data in Investigative Ophthalmology & Visual Science

4DMT announces the publication of preclinical data in Investigative Ophthalmology & Visual Science

Sydney M Crago
December 20th 2024
Article
EssilorLuxottica enters agreement for the acquisition of Espansione Group

EssilorLuxottica enters agreement for the acquisition of Espansione Group

Sydney M Crago
December 19th 2024
Article
AMD-HALT program receives Eurostars grant for continued investigation of dry AMD gene therapy platform

AMD-HALT program receives Eurostars grant for continued investigation of dry AMD gene therapy platform

Hattie Hayes
December 16th 2024
Article
Exegenesis Bio provides an update on EXG102 and EXG202 for wet AMD

Exegenesis Bio provides an update on EXG102 and EXG202 for wet AMD

Sydney M Crago
December 11th 2024
Article
Outlook Therapeutics reveals preliminary topline results of NORSE EIGHT

Outlook Therapeutics reveals preliminary topline results of NORSE EIGHT

Sydney M Crago
December 6th 2024
Article
Galimedix Therapeutics initiates Phase 1 trial of oral GAL-101

Galimedix Therapeutics initiates Phase 1 trial of oral GAL-101

David Hutton
December 6th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.